Cardiac arrest and remifentanil <scp>PCA</scp>

Kranke, Peter; Smith, Andrew F.

doi:10.1111/anae.12244

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pharmacological Methods1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2020

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eleven percent of respondents in a UK survey reported critical incidences relating to the use of remifentanil and respiratory depression . Alarmingly, there have been a number of reported cases of respiratory and cardiac arrest associated with the use of remifentanil PCA . Continuous oxygen saturation monitoring is therefore mandatory during its use.…”

Section: Pharmacological Methodsmentioning

confidence: 99%

Analgesia for labour: an evidence‐based insight for the obstetrician

Alleemudder

Kuponiyi

et al. 2015

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

show abstract

Section: Pharmacological Methodsmentioning

confidence: 99%

Analgesia for labour: an evidence‐based insight for the obstetrician

Alleemudder

Kuponiyi

et al. 2015

The Obstetric & Gynaecologis

View full text Add to dashboard Cite

show abstract

Pain relief during labour: challenging the use of intramuscular pethidine

Kranke

Weibel

2018

The Lancet

View full text Add to dashboard Cite

Remifentanil Patient-controlled Analgesia in Labour: 6-Year Audit of Outcome Data of the RemiPCA SAFE Network (2010-2015)

Melber¹,

Jelting²,

Huber³

et al. 2020

Obstetric Anesthesia Digest

View full text Add to dashboard Cite

(Int J Obstet Anesth. 2019;39:12–21) Remifentanil patient-controlled analgesia (PCA) has been used for ∼20 years during labor as an alternative analgesic approach. While many units utilize this analgesic option in patients who cannot receive neuraxial analgesia, some offer it routinely to their laboring patients. There are some potentially serious side effects of remifentanil PCA, such as respiratory depression and hypoxemia. Swiss researchers developed the RemiPCA SAFE Network in 2009 when the analgesic technique became available in their country. The purpose of the network was to monitor PCA use and assess maternal and neonatal outcomes. While initially developed for Swiss facilities, the network later allowed obstetric units from other countries to participate and provide their data. Data collected by the network helps individual facilities to evaluate their performance and allows the network committee to assess the overall outcomes of remifentanil PCA for labor. The goal of the current audit study was to accurately outline the quality assurance system used by the network and analyze outcomes on remifentanil PCA effectiveness and safety based on the data collected.

show abstract

Cardiac arrest and remifentanil PCA

Cited by 3 publications

References 9 publications

Analgesia for labour: an evidence‐based insight for the obstetrician

Analgesia for labour: an evidence‐based insight for the obstetrician

Pain relief during labour: challenging the use of intramuscular pethidine

Remifentanil Patient-controlled Analgesia in Labour: 6-Year Audit of Outcome Data of the RemiPCA SAFE Network (2010-2015)

Contact Info

Product

Resources

About